In Search of Optimal Criteria for Iron Deficiency in CHF Patients. Post-hoc Analysis of the Study “Prevalence of Iron Deficiency in Patients With Chronic Heart Failure in the Russian Federation (ID-CHF-RF)”

Aim. Comparative analysis of clinical, anamnestic, and laboratory and instrumental data of patients with chronic heart failure (CHF) and iron deficiency (ID) diagnosed according to the AHA/ESC/RSC criteria, and CHF patients diagnosed with ID based on decreased transferrin saturation (TSAT) ≤19.8% or serum iron (Fe) ≤13 μmol/l.
Material and methods. An additional analysis of the ID-CHF-RF study was performed. The analyzed population included 498 patients (198 women) with CHF. In addition to the ID criteria provided by the protocol (AHA/ESC/RSC criteria: ferritin <100 μg/l or ferritin from 100 to 299 μg/l and TSAT<20%), concentrations of ID biomarkers were assessed, which showed high sensitivity and specificity for the diagnosis of ID compared to the morphological picture of the bone marrow (TSAT<19.8% or Fe ≤13 μmol/l). Subgroups of patients with ID determined only by the AHA/ESC/RSC criteria, only by the TSAT≤19.8% and Fe ≤13 μmol/l criteria, and by both were analyzed.
Results. ID diagnosed by the AHA/ESC/RSC criteria was found in 83.1% of patients. The TSAT ≤19.8% and Fe ≤13 μmol/l criteria revealed ID in 74.5% of patients. In 341 patients (76.8%), ID was diagnosed using both criteria. Patients with ID diagnosed by the TSAT≤19.8% and Fe≤13 μmol/l criteria, compared with patients with ID diagnosed by the AHA/ESC/RKO criteria, had a 50% lower Fe (9.8 μmol/l vs. 19.4 μmol/l) and a higher incidence of anemia (43.3% vs. 23.3%) and diabetes mellitus (DM) (36.7% and 24.7%). Also, these patients had higher values of body mass index (BMI) and NT-proBNP concentration (2317 [1305;9092] vs. 1691 [709;3856] pg/ml), and lower LV EF values (41.5 [29.0;54.5]% vs. 45.0 [34.0;54.0]%), respectively. The most severe course of CHF and the greatest changes in laboratory tests associated with ID and anemia were observed in patients with ID determined by two criteria. Patients in this group were older, with a higher BMI, more frequent presence of atrial fibrillation, and higher NT-proBNP (4182 [1854;9341] pg/ml).
Conclusion. Patients with isolated low ferritin are characterized by less severe clinical and functional impairment compared to patients with low TSAT or Fe. At the same time, patients with ferritin higher than 300 μg/l and low TSAT and/or Fe were characterized by very severe CHF and a low functional status, although this may not be related with ID. Thus, the use of the ferritin-based criteria of ID may lead to overdiagnosis of ID in some patients and, at the same time, miss some of the most “severe” patients who likely require the ID correction. Patients with ID who show a decrease in all three parameters are likely to benefit most from Fe supplementation. It is advisable to perform additional studies on the effect of Fe supplements on the course and prognosis of the disease in this cohort of patients.

1. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. и др. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083

2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M и др. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–39. DOI: 10.1093/eurheartj/ehad195

3. Ebner N, Jankowska EA, Ponikowski P, Lainscak M, Elsner S, Sliziuk V и др. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. International Journal of Cardiology. 2016;205:6–12. DOI: 10.1016/j.ijcard.2015.11.178

4. Pratt M, Lewis-Barned N, Walker R, Bailey R, Shand B, Livesey J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. British Journal of Clinical Pharmacology. 1992;34(4):363–5. DOI: 10.1111/j.1365-2125.1992.tb05644.x

5. Grzeslo A, Jankowska EA, Witkowski T, Okonko DO, Majda J, Anker SD и др. Iron deficiency: a frequent and morbid condition in patients with chronic heart failure (4438). European heart journal. 2007;28(Suppl 1):773. [Av. at: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehm420]. DOI: 10.1093/eurheartj/ehm420

6. Arutyunov GP, Bylova NA, Ivleva A, Kobalava ZhD. The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose on patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficincy (ID). European Journal of Heart Failure. 2009. [Av. at: https://www.researchgate.net/publication/285632886]

7. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H и др. Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure. 2009;11(11):1084–91. DOI: 10.1093/eurjhf/hfp140

8. Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J и др. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet. 2020;396(10266):1895–904. DOI: 10.1016/S0140-6736(20)32339-4

9. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB и др. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint tria l. The Lancet. 2022;400(10369):2199–209. DOI: 10.1016/S0140-6736(22)02083-9

10. World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. - Geneva: World Health Organization; 2020. – 62p. ISBN 978-92-4-000012-4

11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM и др. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61. DOI: 10.1161/CIR.0000000000000509

12. McDonagh T, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M и др. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2023;28(1):117–224. DOI: 10.15829/1560-4071-2023-5168

13. Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J и др. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018;29:iv96–110. DOI: 10.1093/annonc/mdx758

14. NICE. Chronic kidney disease: assessment and management. 2021. [Интернет]. Available at: https://www.nice.org.uk/guidance/ng203

15. Grote Beverborg N, Klip IjT, Meijers WC, Voors AA, Vegter EL, van der Wal HH и др. Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure. 2018;11(2):e004519. DOI: 10.1161/CIRCHEARTFAILURE.117.004519

16. Gale E, Torrance J, Bothwell T. The quantitative estimation of total iron stores in human bone marrow. Journal of Clinical Investigation. 1963;42(7):1076–82. DOI: 10.1172/JCI104793

17. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, Van Ede AE и др. Immunochemical and Mass-Spectrometry–Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clinical Chemistry. 2010;56(10):1570–9. DOI: 10.1373/clinchem.2010.149187

18. Graham FJ, Masini G, Pellicori P, Cleland JGF, Greenlaw N, Friday J и др. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. European Journal of Heart Failure. 2022;24(5):807–17. DOI: 10.1002/ejhf.2251

19. Moliner P, Jankowska EA, Van Veldhuisen DJ, Farre N, Rozentryt P, Enjuanes C и др. Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. International Journal of Cardiology. 2017;243:360–6. DOI: 10.1016/j.ijcard.2017.04.110

20. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S и др. Criteria for Iron Deficiency in Patients With Heart Failure. Journal of the American College of Cardiology. 2022;79(4):341–51. DOI: 10.1016/j.jacc.2021.11.039

21. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered Iron Homeostasis in Chronic Heart Failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. Journal of the American College of Cardiology. 2011;58(12):1241–51. DOI: 10.1016/j.jacc.2011.04.040

22. Mareev V.Yu., Begrambekova Yu.L., Mareev Yu.V., Kobalava Zh.D., Karapetyan L.V., Galochkin S.A. и др. Iron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study. Kardiologiia. 2022;62(5):4–8. DOI: 10.18087/cardio.2022.5.n2083

23. Begrambekova Yu.L., Mareev Yu.V., Mareev V.Yu., Orlova Ya.A., Kobalava Zh.D., Karapetyan L.V. и др. Female and Male Phenotypes of Iron Deficiency in CHF. Additional analysis of the “The Prevalence of Iron Deficiency in Patients With Chronic Heart Failure in the Russian Fede ration (J-CHF-RF)” study. Kardiologiia. 2023;63(9):3–13. DOI: 10.18087/cardio.2023.9.n2413

24. Kobalava Zh.D., Lapshin A.A., Tolkacheva V.V., Galochkin S.A. Prevalence and clinical associations of iron deficiency in patients with decompensated heart failure, depending on the diagnostic criteria used for iron deficiency. Therapeutic Archive. 2022;94(7):844–9. DOI: 10.26442/00403660.2022.07.201716

25. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, Van Veldhuisen DJ и др. Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Europea n Heart Journal. 2023;44(48):5077–91. DOI: 10.1093/eurheartj/ehad586

26. Cleland JGF, Kalra PA, Pellicori P, Graham FJ, Foley PWX, Squire IB и др. Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal. 2024;45(16):1410–26. DOI: 10.1093/eurheartj/ehae086

27. Graham FJ, Pellicori P, Masini G, Cuthbert JJ, Clark AL, Cleland JGF. Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure. ESC Heart Failure. 2023;10(5):2826–36. DOI: 10.1002/ehf2.14438